Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland

British Journal of Cancer

Volumn 109, Issue 11, 2013, Pages 2941-2950

  Leinonen, M K ^a   Anttila, A ^a   Malila, N ^a,b   Dillner, J ^c,d   Forslund, O ^c   Nieminen, P ^e  

^a FINNISH CANCER REGISTRY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c LUND UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Age; HPV genotyping; HPV prevalence; HPV screening; HPV types; Human papillomavirus

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SCREENING; COLPOSCOPY; CONTROLLED STUDY; CYTOPATHOLOGY; FEMALE; FINLAND; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; AGE DISTRIBUTION; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; FINLAND; GENOTYPE; HUMANS; MIDDLE AGED; MOLECULAR TYPING; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84888863691     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.647     Document Type: Article

References (49)

1. Agorastos T, Lambropoulos AF, Sotiriadis A, Mikos T, Togaridou E, Emmanouilides CJ (2009) Prevalence and distribution of high-risk human papillomavirus in Greece. Eur J Cancer Prev 18: 504-509.
2. Anchordoquy TJ, Molina MC (2007) Preservation of DNA. Cell Preserv Technol 5: 180-188.
3. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener HG, Herbert A, Daniel J, von Karsa L (eds) (2008) European guidelines for quality assurance in cervical cancer screening 2nd edn. 1-291. European Communities: Belgium.
4. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C (2009) Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 18: 321-330.
5. Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, Bobkiewicz P, Kupryjanczyk J, Krynicki R, Jonska-Gmyrek J, Danska-Bidzinska A, Snijders PJ, Meijer CJ, Zatonski W, Franceschi S (2008) Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer 44: 557-564.
6. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202: 1789-1799.
7. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M (2008) Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 46: 2595-2604.
8. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ (2008) Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98: 646-651. (Pubitemid 351214513)
9. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ (2008) Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl 10): K29-K41.
10. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7: 453-459. (Pubitemid 46962343)
11. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
12. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754.
13. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5): F55-F70.
14. Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B (2002) Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 66: 535-541. (Pubitemid 34203245)
15. Guan P, Howell-Jones R, Bruni L, de Sanjose S, Franceschi S, Clifford GM (2012) Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 131: 2349-2359.
16. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ (2006) Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 44: 3680-3685. (Pubitemid 46768821)
17. Holland NT, Smith MT, Eskenazi B, Bastaki M (2003) Biological sample collection and processing for molecular epidemiological studies. Mutat Res 543: 217-234. (Pubitemid 36645081)
18. Huh W, Einstein MH, Herzog TJ, Franco EL (2010) What is the role of HPV typing in the United States now and in the next five years in a vaccinated population? Gynecol Oncol 117: 481-485.
19. IARC (2012) Biological agents. IARC Monogr Eval Carcinog Risks Hum 100B: 1-498. IARC Press: Lyon.
20. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12: 663-672.
21. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079. (Pubitemid 41417924)
22. Kinney WB, Fetterman B, Cox JT, Lorey T, Flanagan T, Castle PE (2011) Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol 121: 309-313.
23. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T (2008) Population-based prevalence, type-and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123: 1864-1870.
24. Kjaer SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102: 1478-1488.
25. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P (2008) Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 44: 565-571.
26. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, Burk RD (2006) Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 66: 10112-10119. (Pubitemid 44672065)
27. Laukkanen P, Laara E, Koskela P, Pukkala E, Virkkunen H, Lehtinen M (2010) Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses. Future Oncol 6: 709-716.
28. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A (2009) Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 101: 1612-1623.
29. Leinonen MK, Nieminen P, Lonnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A (2012) Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 345: e7789.
30. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
31. Meijer CJ, Snijders PJ, Castle PE (2006) Clinical utility of HPV genotyping. Gynecol Oncol 103: 12-17. (Pubitemid 44374721)
32. Munoz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJLM (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527. (Pubitemid 36159887)
33. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101: 88-99.
34. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J (2007) HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 97: 129-132. (Pubitemid 47012098)
35. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M (2007) Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm 4: 8.
36. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ (2012a) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13: 78-88.
37. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ (2012b) Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130: 602-610.
38. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 102: 315-324.
39. Rothman KJ, Greenland S, Lash TL (2008) Modern Epidemiology. Lippincot Williams & Wilkins: Philadelphia, PA, USA.
40. Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, Peto J, Roberts C, Thomson C, Desai M, Mather J, Kitchener H (2010) Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 48: 554-558.
41. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76-84. (Pubitemid 40725441)
42. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T (2006) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512. (Pubitemid 43222244)
43. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95: 46-52. (Pubitemid 36124295)
44. Shipitsyna E, Zolotoverkhaya E, Kuevda D, Nasonova V, Romanyuk T, Khachaturyan A, Orlova O, Abashova E, Kostyuchek I, Shipulina O, Anttila A, Savicheva A (2011) Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiol 35: 160-164.
45. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632. (Pubitemid 46986496)
46. Soderlund-Strand A, Carlson J, Dillner J (2009) Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 47: 541-546.
47. Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Tornberg S, Dillner J (2011) Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 205(145): e1-e6.
48. Sturegard E, Johansson H, Ekstrom J, Hansson BG, Johnsson A, Gustafsson E, Dillner J, Forslund O (2013) Human papillomavirus typing in reporting of condyloma. Sex Transm Dis 40: 123-129.
49. Ucakar V, Poljak M, Klavs I (2012) Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: a cervical cancer screening based study. Vaccine 30: 116-120.